Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy.
Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy.
Biomed Pharmacother. 2022 Jun;150:113013. doi: 10.1016/j.biopha.2022.113013. Epub 2022 Apr 30.
The 97% of dementia patients develops fluctuant neuropsychiatric symptoms often related to under-diagnosed and unrelieved pain. Up to 80% severe demented nursing home residents experiences chronic pain due to age-related comorbidities. Patients lacking self-report skills risk not to be appropriately treated for pain. Mobilization-Observation-Behavior-Intensity-Dementia (MOBID2) is the sole pain scale to consider the frequent co-occurrence of musculoskeletal and visceral pain and to unravel concealed pain through active guided movements. Accordingly, the Italian real-world setting can benefit from its translation and validation. This clinical study provides a translated, adapted and validated version of the MOBID2, the Italian I-MOBID2. The translation, adaptation and validation of the scale for non-verbal, severe demented patients was conducted according to current guidelines in a cohort of 11 patients over 65 with mini-mental state examination ≤ 12. The I-MOBID2 proves: good face and scale content validity index (0.89); reliable internal consistency (Cronbach's α = 0.751); good to excellent inter-rater (Intraclass correlation coefficient, and test-retest (ICC = 0.902) reliability. The construct validity is high (Rho = 0.748 p < 0.05 for 11 patients, Spearman rank order correlation of the overall pain intensity score with the maximum item score of I-MOBID2 Part 1; rho=0.895 p < 0.01 for 11 patients, for the overall pain intensity score with the maximum item score of I-MOBID2 Part 2) and a good rate of inter-rater and test-retest agreement was demonstrated by Cohen's K = 0.744. The average execution time is of 5.8 min, thus making I-MOBID2 a useful tool suitable also for future development in community setting with administration by caregivers.
97%的痴呆症患者会出现波动性神经精神症状,这些症状通常与未被诊断和未缓解的疼痛有关。高达 80%的严重痴呆养老院居民因与年龄相关的合并症而经历慢性疼痛。缺乏自我报告技能的患者可能无法得到适当的疼痛治疗。MOBID2(活动观察行为强度痴呆)是唯一一种考虑到肌肉骨骼和内脏疼痛频繁同时发生并通过主动引导运动来揭示隐匿性疼痛的疼痛量表。因此,意大利的真实环境可以从其翻译和验证中受益。本临床研究提供了 MOBID2 的翻译、改编和验证版本,即意大利语 I-MOBID2。在一个由 11 名年龄在 65 岁以上、迷你精神状态检查≤12 的患者组成的队列中,根据当前指南对该量表进行了非言语、严重痴呆患者的翻译、改编和验证。I-MOBID2 证明:良好的表面和量表内容效度指数(0.89);可靠的内部一致性(Cronbach's α=0.751);良好至优秀的评分者间信度(组内相关系数和重测信度(ICC=0.902)。结构效度高(Rho=0.748,p<0.05,对 11 名患者,I-MOBID2 第 1 部分整体疼痛强度评分与最大项目评分的 Spearman 秩相关;rho=0.895,p<0.01,对 11 名患者,I-MOBID2 第 2 部分整体疼痛强度评分与最大项目评分的 Spearman 秩相关),评分者间和重测信度一致性良好,Cohen's K=0.744。平均执行时间为 5.8 分钟,因此 I-MOBID2 是一种有用的工具,也适合在社区环境中由护理人员进行管理。